Core Viewpoint - Analysts expect Old Dominion Freight Line (ODFL) to report quarterly earnings of $1.14 per share, reflecting a year-over-year decline of 14.9%, with revenues projected at $1.37 billion, down 6.3% from the previous year [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 4.4%, indicating a collective reassessment by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue and Key Metrics - Analysts estimate 'Total revenue- Other services' to be $13.37 million, showing a year-over-year increase of 0.2% [5]. - 'Total revenue- LTL services' is forecasted to reach $1.35 billion, indicating a decline of 6.5% year-over-year [5]. - The expected 'Operating Ratio' is 76.3%, up from 73.5% in the same quarter last year [5]. LTL Performance Metrics - 'LTL tonnage per day' is projected at 33.40 Kton/D, down from 35.38 Kton/D a year ago [6]. - 'LTL shipments per day' are expected to be 44.47 thousand, compared to 46.93 thousand in the same quarter last year [6]. - 'LTL revenue per hundredweight' is estimated at $32.62, up from $31.98 a year ago [6]. Additional LTL Metrics - 'LTL revenue per hundredweight, excluding fuel surcharges' is projected at $27.84, compared to $26.78 last year [7]. - 'LTL shipments' are expected to reach 2,801, down from 3,004 in the same quarter last year [7]. - 'LTL tons' are forecasted at 2,079.28 KTon, down from 2,264 KTon a year ago [8]. Shipment and Weight Metrics - The average 'LTL weight per shipment' is estimated at 1,484.92 lbs, compared to 1,508 lbs last year [8]. - 'Work days' are projected to be 63.00 days, down from 64 days a year ago [8]. - 'LTL revenue per shipment' is expected to be $483.32, slightly up from $482.24 in the same quarter last year [9]. Stock Performance - Over the past month, shares of Old Dominion have declined by 6.9%, compared to a 5.6% decline in the Zacks S&P 500 composite [9]. - Currently, ODFL holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [10].

Core Viewpoint - Freeport-McMoRan (FCX) is expected to report a decline in quarterly earnings and revenues, with analysts predicting earnings of $0.24 per share, a 25% decrease year-over-year, and revenues of $5.31 billion, reflecting a 16% decline compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has been revised upward by 9.8% over the past 30 days, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Estimates - Analysts estimate 'Revenues- Indonesia' at $1.31 billion, a decrease of 53.6% from the prior-year quarter [5]. - 'Revenues- Molybdenum' are expected to reach $261.94 million, showing an increase of 80.7% year-over-year [5]. - 'Revenues- South America copper mines' are projected at $1.29 billion, indicating a year-over-year increase of 13.9% [5]. - 'Revenues- North America copper mines' are forecasted to be $1.56 billion, reflecting a 3.9% increase year-over-year [6]. Production and Sales Estimates - 'Production in millions of pounds - Molybdenum - South America (Cerro Verde)' is expected to be 5.82 Mlbs, up from 3 Mlbs in the same quarter last year [7]. - 'Production in millions of pounds - Molybdenum - By-product - North America' is estimated at 7.73 Mlbs, compared to 7 Mlbs reported in the same quarter last year [7]. - 'Sales in thousands of Ounces - Gold - North America' are projected at 3.87 Koz, down from 4 Koz in the same quarter last year [8]. - 'Sales in thousands of ounces - Gold - Consolidated basis' are expected to reach 126.13 Koz, significantly lower than 568 Koz reported in the same quarter last year [8]. - 'Sales in thousands of Ounces - Gold - Indonesia' are estimated at 122.25 Koz, down from 564 Koz year-over-year [9]. - 'Sales in millions of pounds - Copper - Total South America' are projected at 281.86 Mlbs, slightly lower than 284 Mlbs reported in the same quarter last year [9]. - 'Sales in millions of pounds - Copper - Indonesia - Grasberg' are expected to be 242.98 Mlbs, down from 493 Mlbs year-over-year [10]. Stock Performance - Freeport-McMoRan shares have decreased by 19.2% over the past month, contrasting with a 6.9% decline in the Zacks S&P 500 composite [11].

Core Viewpoint - Analysts expect Gilead Sciences to report quarterly earnings of $1.73 per share, reflecting a year-over-year increase of 231.1%, with revenues projected at $6.83 billion, up 2.2% from the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 0.9% in the past 30 days, indicating a reassessment of initial estimates by covering analysts [1][2]. Revenue and Product Sales Projections - Total product sales are expected to reach $6.75 billion, indicating a year-over-year change of +1.6% [4]. - Royalty contract and other revenues are estimated at $40.04 million, reflecting a +2.7% change from the prior year [4]. - Product Sales for HIV (Genvoya) are projected at $375.96 million, showing a decline of -6.7% year over year [4]. - Product Sales for HIV (Odefsey) are expected to be $294.72 million, down -4.9% from the previous year [5]. - Oncology product sales (Tecartus) are forecasted at $56.12 million, indicating a +2% change [5]. - Liver Disease product sales (Sofosbuvir/Velpatasvir) are estimated at $238.12 million, down -4% from the year-ago quarter [6]. - Other product sales (Other) are projected at $40.07 million, reflecting a significant decline of -32.1% [6]. - Total HIV product sales in the U.S. are expected to reach $3.56 billion, indicating a +4.6% change year over year [7]. Additional Product Sales Insights - Product Sales for HIV (Genvoya) in the U.S. are projected at $299.29 million, down -9.9% from the previous year [7]. - Liver Disease product sales (Vemlidy) are expected to be $96.60 million, reflecting a +1.7% change [8]. - Other product sales (AmBisome) are projected at $11.31 million, down -19.2% from the prior year [8]. - Product Sales for Veklury are expected to be $277.30 million, indicating a -12% change year over year [8]. Stock Performance - Gilead shares have experienced a -1.3% change over the past month, compared to a -6.9% move in the Zacks S&P 500 composite [9].

Core Viewpoint - Analysts expect Edwards Lifesciences to report quarterly earnings of $0.60 per share, reflecting a year-over-year decline of 9.1%, with revenues projected at $1.4 billion, down 12.2% from the previous year [1] Earnings Estimates - Changes in earnings estimates are crucial for predicting investor reactions to stock performance, with empirical studies showing a strong correlation between earnings estimate revisions and short-term price performance [2] Key Metrics Overview - Analysts predict 'Net Sales by Product Group- Transcatheter Mitral and Tricuspid Therapies' will reach $113.82 million, indicating a year-over-year increase of 56.1% [4] - 'Net Sales by Product Group- Surgical Structural Heart' is forecasted to be $254.51 million, reflecting a decrease of 4.4% from the year-ago quarter [4] - 'Net Sales by Product Group- Transcatheter Aortic Valve Replacement' is expected to reach $1.03 billion, showing a year-over-year increase of 2.2% [5] - 'Net Sales- Europe' is projected at $357.01 million, indicating a decline of 2.9% from the prior-year quarter [5] - 'Net Sales- Outside of the United States' is estimated at $573.77 million, reflecting a year-over-year decrease of 12.7% [6] - 'Net Sales- United States' is expected to be $849.03 million, down 9.8% from the previous year [6] - 'Net Sales- Japan' is projected to reach $96.40 million, indicating a year-over-year decline of 13% [6] - 'Net Sales- Rest of World' is expected to be $120.36 million, reflecting a significant decrease of 32.7% from the year-ago quarter [7] Stock Performance - Edwards Lifesciences shares have increased by 0.8% over the past month, contrasting with the Zacks S&P 500 composite's decline of 6.9%, with a Zacks Rank of 3 (Hold) indicating expected performance in line with the overall market [7]

Wall Street analysts expect Dow Inc. (DOW) to post quarterly loss of $0.02 per share in its upcoming report, which indicates a year-over-year decline of 103.6%. Revenues are expected to be $10.27 billion, down 4.6% from the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 46% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a compan ...

Wall Street analysts expect Nasdaq (NDAQ) to post quarterly earnings of $0.77 per share in its upcoming report, which indicates a year-over-year increase of 22.2%. Revenues are expected to be $1.23 billion, up 10.2% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings announ ...

Core Viewpoint - Analysts forecast Merck's quarterly earnings to be $2.16 per share, reflecting a year-over-year increase of 4.4%, while revenues are expected to decline by 1.9% to $15.48 billion [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 4%, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock performance [3]. Key Metrics Projections - Sales for Oncology product Keytruda are projected to reach $7.55 billion, an increase of 8.7% year-over-year [5]. - Hospital Acute Care sales for Zerbaxa are expected to be $63.07 million, reflecting a 12.6% increase from the previous year [5]. - Alliance revenue for Lynparza is estimated at $300.62 million, indicating a 3% increase year-over-year [5]. - Sales for Oncology Alliance revenue Lenvima are projected at $234.33 million, showing an 8.1% decline from the prior year [6]. - U.S. sales for Keytruda are expected to be $4.47 billion, reflecting an 8.6% increase year-over-year [6]. - International sales for Keytruda are projected at $3.08 billion, indicating an 8.8% increase from the previous year [7]. - U.S. sales for Lynparza are expected to reach $121.96 million, reflecting a 9.7% decline year-over-year [7]. - International sales for Lynparza are projected at $178.66 million, indicating a 13.8% increase from the prior year [8]. - U.S. sales for Lenvima are expected to be $155.59 million, reflecting a 10.1% decline year-over-year [8]. - International sales for Lenvima are projected at $78.74 million, indicating a 4% decline from the previous year [9]. - U.S. sales for Zerbaxa are expected to reach $36.81 million, reflecting an 11.5% increase year-over-year [9]. - International sales for Zerbaxa are projected at $26.26 million, indicating a 14.2% increase from the prior year [10]. Stock Performance - Merck's shares have decreased by 17.7% over the past month, compared to a 6.9% decline in the Zacks S&P 500 composite [10].

Core Viewpoint - The upcoming earnings report from Ameriprise Financial Services (AMP) is anticipated to show an increase in quarterly earnings and revenues compared to the previous year, with earnings per share expected to be $9.12, reflecting an 8.7% increase, and revenues projected at $4.39 billion, indicating a 7.1% year-over-year growth [1]. Earnings Estimates - The consensus EPS estimate has been revised 3.8% lower over the last 30 days, indicating a reevaluation by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts expect 'Revenues- Net investment income' to be $845.60 million, a decrease of 6.2% from the previous year [5]. - 'Revenues- Premiums, policy and contract charges' are projected to reach $391.68 million, showing a slight increase of 0.4% year-over-year [5]. - 'Revenues- Distribution fees' are estimated at $534.87 million, reflecting a 5.7% increase compared to the year-ago quarter [5]. - 'Revenues- Other revenues' are forecasted to be $132.12 million, indicating a 2.4% increase year-over-year [6]. Assets Under Management - Total Assets Under Management (AUM) is expected to reach $1.18 billion, up from $1.13 billion in the same quarter last year [6]. - Total Assets Under Administration are projected at $317.49 million, compared to $297.46 million in the previous year [7]. - Total Assets Under Management and Administration are estimated to be $1.49 billion, an increase from $1.42 billion year-over-year [7]. - AUM for Asset Management is expected to be $646.27 million, slightly down from $652.08 million in the same quarter last year [8]. - Total Client Assets are projected to reach $1,030.12 billion, up from $953.77 billion year-over-year [9]. Advisor Metrics - The number of total advisors is expected to reach 10,450, compared to 10,364 in the previous year [9]. Stock Performance - Ameriprise shares have decreased by 5.8% over the past month, while the Zacks S&P 500 composite has declined by 6.9% [11].

Company Overview - Masimo Corporation (MASI) is positioned as an intriguing investment choice within the Medical - Instruments sector, supported by solid earnings estimate revisions [1][3]. - The company has experienced a positive shift in earnings estimates, indicating a more bullish outlook from analysts regarding its short and long-term prospects [3]. Industry Context - The Medical - Instruments industry currently holds a Zacks Industry Rank of 66 out of over 250 industries, suggesting a favorable position compared to other sectors [2]. - The industry is experiencing broad trends that are positively impacting securities across the board, indicating a rising tide effect [2]. Earnings Estimates - Over the past month, Masimo's current quarter earnings estimates have increased from $1.17 per share to $1.24 per share, while current year estimates have risen from $5.07 per share to $5.28 per share [4]. - These revisions have contributed to Masimo earning a Zacks Rank 1 (Strong Buy), highlighting the company's strong market position [4]. Investment Consideration - Given the strong performance of the industry and the positive earnings revisions, Masimo is recommended as a compelling option for investors seeking opportunities in a robust industry segment [5].

Wall Street expects a year-over-year increase in earnings on lower revenues when Merck (MRK) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 24. On the othe ...